Key Takeaways Amarin posted adjusted Q3 earnings of 1 cent per share, missing the estimated 8 cents.Quarterly revenues rose 17% year over year to $49.7 million, topping expectations.U.S. Vascepa sales surged 34%, offsetting weaker European and rest-of-world revenues.Amarin Corporation (AMRN) reported adjusted earnings of 1 cent per share for the third quarter of 2025, which missed the Zacks Consensus Estimate of 8 cents per share. The company had reported an adjusted loss of 5 cents per share in the year-ag ...

Bristol Myers Squibb added nearly $1 billion to its bottom line in the third quarter as costs came down and revenue climbed on the strength of its newer drugs https://t.co/qsE7vy4aLW ...

Lantern Pharma Conference Call Summary Company Overview - **Company**: Lantern Pharma (NasdaqCM: LTRN) - **Focus**: AI-driven drug development, particularly in oncology, utilizing proprietary AI platforms to identify and develop targeted therapies [1][2] Key Points and Arguments AI and Drug Development - Lantern Pharma has developed **12 drug programs** since late 2018, with **three currently in clinical trials** [2] - The company emphasizes the use of AI to accelerate drug discovery, aiming to make the process faster and more cost-effective [2][3] - The AI platform has evolved significantly, reducing the time to update and improve its capabilities from over a year to less than four months [6][16] Clinical Trials and Drug Candidates - **LP-300**: Targeting lung cancer in non-smokers, currently in Phase 2 trials. This demographic represents about **17% of lung cancer cases in the U.S.** and **35-40% in East Asia** [5][27] - **LP-284**: A drug for non-Hodgkin's lymphoma showing complete metabolic response in trials. It is positioned as a potential blockbuster with a market potential of over **$10 billion** [6][31] - **LP-184**: Targets cancers with DNA damage repair deficiencies, with a market potential of over **$4 billion**. It has shown promising results in various cancers, including lung and triple-negative breast cancer [32][27] Business Model and Market Strategy - Lantern Pharma's business model includes repositioning existing drugs and developing new ones, with a focus on precision oncology [4][9] - The company plans to monetize its AI platform through a **freemium model**, allowing other cancer drug developers to access its technology [7][19] - The company is also preparing to spin out **Starlight Therapeutics**, focusing exclusively on brain cancers, which could enhance its market valuation [11][12] Financials and Market Position - As of the last quarter, Lantern Pharma reported approximately **$15.9 million** in cash with a burn rate of **$4 to $4.5 million** per quarter [36] - The company has not raised capital since January 2021 and has no toxic financial events or warrants [36] Regulatory Environment - The FDA is increasingly focusing on AI models in drug development, which could benefit Lantern Pharma's initiatives, especially in pediatric cancers [36][37] - Lantern has received multiple rare pediatric designations, enhancing its potential for market success [37] Additional Important Insights - The company is actively engaging with pharmaceutical companies for potential partnerships, although challenges exist due to industry skepticism towards AI [21][22] - Lantern Pharma's approach to drug development is characterized by a willingness to explore multiple avenues simultaneously, reflecting a strategy to mitigate risks in a highly uncertain field [24][26] - The company believes that the future of medicine will increasingly rely on AI, positioning itself as a leader in this transformative space [27] This summary encapsulates the critical aspects of Lantern Pharma's conference call, highlighting its innovative approach to drug development, clinical advancements, and strategic positioning in the oncology market.

Merck & Co., Inc. (NYSE:MRK) stock traded in a volatile session on Thursday following its third-quarter earnings report and updated fiscal 2025 outlook.The pharma giant reported adjusted earnings per share of $2.58, surpassing consensus estimates of $2.35, a jump from $1.57 reported a year ago.Merck reported sales of $17.28 billion, a 4% increase year-over-year, and exceeded the analysts’ projections of $16.96 billion.Also Read: Merck’s New Cancer Therapy Combo Shows Significant Edge Over Rivals In Renal Ca ...

Accessibility StatementSkip Navigation "We're proud to support the advancement of ratutrelvir from discovery through clinical development," said Ilya Baimetov, COO at ChemDiv. "By combining our integrated medicinal chemistry capabilities with Molsoft's rational design tools and Expert Systems' AI-driven predictive pharmacology, we created a differentiated COVID therapeutic with best-in-class potential. Our continued CMC support ensures Traws has the manufacturing infrastructure and analytical capabilities ...

Core Insights - Eli Lilly's experimental weight-loss pill, orforglipron, is a strong candidate for accelerated FDA approval due to meeting most criteria for the new national priority voucher program [1][2] - The FDA's new program allows for expedited reviews of priority drugs, reducing the review time from approximately 10-12 months to 1-2 months [2] - Eli Lilly's GLP-1 pill demonstrated a significant weight loss of 12.4% in late-stage studies, and the company has invested billions in U.S. manufacturing plants for this product [3] Financial Performance - Eli Lilly raised its full-year profit and revenue forecasts, driven by strong international demand for weight-loss drugs, surpassing Wall Street's earnings expectations for the third quarter [4] - International sales of Mounjaro, the brand name for the weight-loss drug outside the U.S., exceeded Guggenheim analysts' estimates by nearly $1 billion for the quarter [6] - Approximately 75% of Mounjaro's revenue from international markets comes from out-of-pocket payments by individuals with obesity [6] Market Competition - Eli Lilly is competing with Novo Nordisk in the weight-loss drug market, which is projected to reach $150 billion by the end of the decade [7] - The company faces potential challenges from drug price negotiations under the Trump administration, which aims to align U.S. drug prices with those in other developed nations [4][7]

More than half a million bottles of blood pressure medication have been recalled over high levels of a chemical compound that could cause cancer, the Food and Drug Administration said.Parsippany, NJ-based Teva Pharmaceuticals USA recalled 580,844 bottles of Prazosin Hydrochloride earlier this month.The medication is an alpha blocker taken to lower high blood pressure.More than half a million bottles of blood pressure medication have been recalled. Teva PharmaceuticalsTesting revealed high levels of “N-nitro ...

Key Takeaways Bristol-Myers posted Q3 EPS of $1.63 and revenues of $12.2B, topping consensus estimates.Growth Portfolio sales climbed 18% to $6.8B, led by Opdivo, Reblozyl, Breyanzi and Camzyos.Legacy drugs declined but Eliquis surged 25%. Bristol-Myers Squibb Company (BMY) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.63, which comfortably beat the Zacks Consensus Estimate of $1.48. In the year-ago quarter, BMY posted adjusted earnings per share of $1.80.Total revenues of $12.2 billio ...

Courtesy of Cardinal Health Cardinal Health (NYSE: CAH) delivered a commanding first quarter for fiscal 2026, beating both earnings and revenue expectations by wide margins while raising full-year guidance. The stock climbed 1% in early trading as investors digested results that extend a perfect eight-quarter beat streak. A Quarter of Broad Execution Non-GAAP earnings per share came in at $2.55, crushing the $2.21 consensus by 16%. Revenue hit $64.0B, topping estimates of $59.79B by 7%. What matters here ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In aTyr To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in aTyr between January 16, 2025 and September 12, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Faruqi & ...